Objective: The primary objective of this study was to evaluate the physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials during simulated Y-site administration.

Methods: Ceftazidime-avibactam (25 mg/mL) was mixed with select intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) at an equal volume and evaluated using simulated Y-sites. Each admixture was evaluated immediately (0 hour) and after 1, 2, and 4 hours at room temperature (approximately 22°C) for visual characteristics, Tyndall beam, turbidity, pH, spectroscopic absorption of 550 nm and particle counts. If an admixture failed any one of these six assessments, it was considered incompatible.

Results: No evidence of incompatibility was observed between the combinations of ceftazidime-avibactam and the seven intravenous antimicrobials in simulated Y-site experiments.

Conclusion: Ceftazidime-avibactam was physically compatible with the selected intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) in simulated Y-site administration.

Chen F, Ding H, Liu S, Chen Z, Tang L, Tong T. Physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials in simulated Y-site administration. Eur J Hosp Pharm. 2025 Mar 3:ejhpharm-2024-004358. doi: 10.1136/ejhpharm-2024-004358. Epub ahead of print. PMID: 40032507.